Scientists have identified a set of 10 proteins in the blood that can predict the onset of Alzheimer’s, marking a significant step towards developing a blood test for the disease.
The study, led by King’s College London and proteomics company, Proteome Sciences plc, analysed data from 3 international studies. Blood samples from a total of 1,148 individuals (476 with Alzheimer’s disease; 220 with ‘mild cognitive impairment’ (MCI) and 452 elderly controls without dementia) were analysed for 26 proteins previously shown to be associated with Alzheimer’s disease. A sub-group of 476 individuals across all three groups also had an MRI brain scan.
Lead author Dr Abdul Hye said: “Memory problems are very common, but the challenge is identifying who is likely to develop dementia. There are thousands of proteins in the blood, and this study is the culmination of many years’ work identifying which ones are clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment, will develop Alzheimer’s disease within a year, with a high level of accuracy.”
In the study, published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, researchers identified 16 of these 26 proteins to be strongly associated with brain shrinkage in either MCI or Alzheimer’s. They then ran a second series of tests to establish which of these proteins could predict the progression from MCI to Alzheimer’s. They identified a combination of 10 proteins capable of predicting whether individuals with MCI would develop Alzheimer’s disease within a year, with an accuracy of 87%.
Dr Ian Pike, co-author of the paper from Proteome Sciences, hailed the study as a “major advance” in the development of a simple blood test to identify the disease before clinical symptoms appear, and noted the financial implications of it.
Professor Simon Lovestone concluded: “Alzheimer’s begins to affect the brain many years before patients are diagnosed with the disease. Many of our drug trials fail because by the time patients are given the drugs, the brain has already been too severely affected. A simple blood test could help us identify patients at a much earlier stage to take part in new trials and hopefully develop treatments which could prevent the progression of the disease. The next step will be to validate our findings in further sample sets, to see if we can improve accuracy and reduce the risk of misdiagnosis, and to develop a reliable test suitable to be used by doctors.”
Key step to delivering effective early Alzheimer's treatment
There are currently no effective long-lasting drug treatments for Alzheimer’s, and it is believed that many clinical trials fail because drugs are given too late in the disease process. A blood test could be used to identify patients in the early stages of memory loss for clinical trials to find drugs to halt the progression of the disease.
Dr Eric Karran, director of research at Alzheimer’s Research UK, added: “With an ageing population, and age the biggest risk factor for Alzheimer’s, we are expecting rising numbers of people to be affected over the coming years. It’s important to develop new ways to intervene early in the disease to help people maintain their quality of life for as long as possible.”
“We are in the process of selecting commercial partners to combine the protein biomarkers in a blood test for the global market, a key step forward to deliver effective and early treatment for this crippling disease.”